Kaplan-Meier survival curves of gastric carcinoma patients with and without tumor expression of PRR11.
Figures are generally photos, graphs and static images that would be represented in traditional pdf publications.
(A) Survival was significantly longer in patients with tumor lacking expression of PRR11 (OS, 76.6 month) versus those with positive PRR11 expression status (OS, 46.6 month; P < 0.001). (B) A subgroup analysis of stage I & II patients revealed that patients with a positive PRR11 expression status was associated with a shorter survival duration than patients without PRR11 expression (58.5mon vs. 97.9mon; P<0.001). (C) A subgroup analysis of stage III & IV patients demonstrated that positive PRR11 overexpression was associated with a shorter overall survival than patients without PRR11 expression (34.3mon vs. 51.3mon; P = 0.036).